Thermo Fisher Scientific (BASE:TMOD) - Aktienkurs, Nachrichten und Analyse

TMOD Aktienübersicht

Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.

Über das Unternehmen

TMOD grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	1/6
Vergangene Leistung	2/6
Finanzielle Gesundheit	3/6
Dividenden	4/6

Belohnungen

Prognostiziertes Gewinnwachstum 15.54% pro Jahr

Risikoanalyse

Aktien sind hochgradig illiquide

Hat einen hohen Schuldenstand

Thermo Fisher Scientific Inc. Wettbewerber

Danaher

NYSE:DHR

US$185.1b

Lonza Group

SWX:LONN

CHF 35.4b

IQVIA Holdings

NYSE:IQV

US$38.5b

Agilent Technologies

NYSE:A

US$37.8b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Thermo Fisher Scientific
Historische Aktienkurse
Aktueller Aktienkurs	US$27.00
52-Wochen-Hoch	US$27.00
52-Wochen-Tief	US$27.00
Beta	0.77
11 Monat Veränderung	0%
3 Monate Veränderung	n/a
1 Jahr Veränderung	n/a
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	0%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	TMOD	AR Life Sciences	AR Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie TMOD im Vergleich zur Branche AR Life Sciences abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie TMOD im Vergleich zum AR Markt abgeschnitten hat.

Preisvolatilität

Is TMOD's price volatile compared to industry and market?
TMOD volatility
TMOD Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in AR Market	0%
10% least volatile stocks in AR Market	0%

Stabiler Aktienkurs: TMOD hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von TMOD im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1956	130,000	Marc Casper	www.thermofisher.com

Thermo Fisher Scientific Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Thermo Fisher Scientific im Vergleich zum Marktanteil des Unternehmens?
TMOD grundlegende Statistiken
Marktanteil	US$200.29b
Gewinn(TTM)	US$6.02b
Umsatz(TTM)	US$43.81b

33.2x

Kurs-Gewinn-Verhältnis

4.6x

Kurs-Umsatz-Verhältnis

Ist TMOD zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
TMOD Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$43.81b
Kosten der Einnahmen	US$26.10b
Bruttogewinn	US$17.71b
Sonstige Ausgaben	US$11.68b
Umsatz	US$6.02b

Zuletzt gemeldete Gewinne

Apr 01, 2023

Datum des nächsten Gewinnberichts

Jul 26, 2023

Gewinn per Aktie (EPS)	15.62
Bruttomarge	40.42%
Nettogewinnspanne	13.75%
Schulden/Eigenkapital-Verhältnis	82.8%

Wie hat sich TMOD auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

0.3%

Aktuelle Dividendenrendite

8%

Ausschüttungsquote

TMOD Aktienübersicht

Belohnungen

Risikoanalyse

Thermo Fisher Scientific Inc. Wettbewerber

NYSE:DHR

US$185.1b

SWX:LONN

CHF 35.4b

NYSE:IQV

US$38.5b

NYSE:A

US$37.8b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies

Thermo Fisher Scientific Introduces Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2024

Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

Recent updates

Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies

Thermo Fisher Scientific Introduces Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2024

Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024

Thermo Fisher Scientific Inc. Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024

Thermo Fisher Scientific Introduces Its Newest Line of High Performance, Ultra-Low Temperature (ULT) Freezers

Thermo Fisher Scientific Inc. to Report Q1, 2024 Results on Apr 24, 2024

Thermo Fisher Scientific Announces A New In-Line Metrology Solution to Improve Battery Safety and Performance

Thermo Fisher Scientific Inc. Launches Corevitas Clinical Registry in Generalized Pustular Psoriasis

Thermo Fisher Scientific Inc. Increases Quarterly Cash Dividend, Payable on April 15, 2024

Thermo Fisher Scientific Inc. Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing

Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024

Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia

Thermo Fisher Scientific Receives GMP Approval from the Italian Medicines Agency for its Manufacturing Facility of RNA-Based Products in Monza, Italy

Thermo Fisher Scientific Inc. Announces Launch of Innovative Corevitas Pharmacovigilance Platform for Clinical Research Registries

Thermo Fisher Scientific Inc. Announces the Launch of the Thermo Scientific KingFisher Apex Dx and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit

Thermo Fisher Scientific Declares Quarterly Dividend, Payable on January 16, 202

Thermo Fisher Scientific Announces New Fault Localization Solution for the Analysis of Advanced Logic Semiconductors

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. to Report Q3, 2023 Results on Oct 25, 2023

Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee

Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with A Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™

Thermo Fisher Scientific Announces the Launch of the EXENT Solution with IVDR Certification

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Thermo Fisher Scientific Inc. (NYSE:TMO) acquired CorEvitas, LLC from Audax Management Company, LLC for approximately $910 million.

Thermo Fisher Scientific Announces a New Line of Thermo Scientific TM TSG Series Refrigerators

Thermo Fisher Scientific Inc. Revises earnings Guidance for 2023

Thermo Fisher Scientific Introduces New Reproductive Health Assays to Accelerate Fertility Research

Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors

Thermo Fisher Scientific Inc. (NYSE:TMO) has entered into a definitive agreement to acquire CorEvitas, LLC from Audax Management Company, LLC for Approximately $910 million.

Thermo Fisher May Be Leading Bidder to Buy CorEvitas

Thermo Fisher Scientific Announces Launch of Gibco™ OncoPro™ Tumoroid Culture Medium Kit

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition MarqMetrix, Inc.

Thermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery

Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on July 14, 2023

Montrose Environmental Group, Inc. Announces Global Collaboration with Thermo Fisher Scientific Inc. to Provide A Comprehensive Real-Time Ethylene Oxide Monitoring Solution Meets Recent Release U.S. Environmental Protection Agency Regulations

Thermo Fisher Scientific Inc., Annual General Meeting, May 24, 2023

Warburg, Advent Reportedly in Lead to Acquire Baxter's Biopharma Unit

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Thermo Fisher Scientific Inc.'s Grundlagenzusammenfassung

33.2x

4.6x

Erträge &amp; Einnahmen

Dividenden

0.3%

8%

Erträge & Einnahmen